The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
 
Mikkael A. Sekeres
Consulting or Advisory Role - Celgene; Millennium
 
Robert J. Fram
Employment - Millennium
Stock and Other Ownership Interests - Baxter; Bristol-Myers Squibb; Mersana; Pfizer; Shire; Teva
Consulting or Advisory Role - BeyondSpring Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Vertex
 
Zhaowei Hua
Employment - Millennium
Stock and Other Ownership Interests - Celgene (I); Gilead Sciences (I)
Travel, Accommodations, Expenses - Takeda
 
Lionel Ades
Consulting or Advisory Role - Celgene; Novartis; Takeda
Research Funding - Celgene (Inst)